• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees.

作者信息

Yadav Pragya D, Sapkal Gajanan N, Abraham Priya, Ella Raches, Deshpande Gururaj, Patil Deepak Y, Nyayanit Dimpal A, Gupta Nivedita, Sahay Rima R, Shete Anita M, Panda Samiran, Bhargava Balram, Mohan V Krishna

机构信息

Indian Council of Medical Research-National Institute of Virology, Pune, India.

Bharat Biotech International Limited, Genome Valley, Hyderabad, India.

出版信息

Clin Infect Dis. 2022 Jan 29;74(2):366-368. doi: 10.1093/cid/ciab411.

DOI:10.1093/cid/ciab411
PMID:33961693
Abstract
摘要

相似文献

1
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees.用BBV152疫苗接种者的血清中和正在研究的变异株B.1.617.1
Clin Infect Dis. 2022 Jan 29;74(2):366-368. doi: 10.1093/cid/ciab411.
2
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152.与接种 BBV152 的个体血清相比，对 SARS-CoV-2 Delta AY.1 和 Delta 的中和作用相当。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab154.
3
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.用 COVID-19 恢复期患者和灭活 COVID-19 疫苗 BBV152/Covaxin 接种者的血清中和 Beta 和 Delta 变异株。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab104.
4
Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals.用Covishield™疫苗接种者和新冠康复后接种疫苗者的血清中和德尔塔变种。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab119.
5
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
6
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.灭活新冠疫苗BBV152/COVAXIN可有效中和最近出现的新冠病毒B.1.1.7变异株。
J Travel Med. 2021 Jun 1;28(4). doi: 10.1093/jtm/taab051.
7
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.BNT162b2 或科兴疫苗接种者血清对严重急性呼吸综合征冠状病毒 2 奥密克戎变异株的中和作用。
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826. doi: 10.1093/cid/ciab1041.
8
Serum neutralization assay can efficiently replace plaque reduction neutralization test for detection and quantitation of West Nile virus antibodies in human and animal serum samples.血清中和试验可有效替代蚀斑减少中和试验，用于检测和定量人及动物血清样本中的西尼罗河病毒抗体。
Clin Vaccine Immunol. 2014 Oct;21(10):1460-2. doi: 10.1128/CVI.00426-14. Epub 2014 Aug 6.
9
Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera.SARS-CoV-2 刺突特异性抗血清分析方法的比较研究。
Viruses. 2022 Feb 17;14(2):410. doi: 10.3390/v14020410.
10
Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.奥密克戎变异株感染个体的恢复期血清中不存在针对原始 SARS-CoV-2 病毒或其伽马变异株的中和抗体。
Clinics (Sao Paulo). 2022 Jun 16;77:100068. doi: 10.1016/j.clinsp.2022.100068. eCollection 2022.

引用本文的文献

1
Low-frequency CD8 T cells induced by SIGN-R1 macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice.通过靶向SIGN-R1巨噬细胞的疫苗诱导的低频CD8 T细胞可清除小鼠体内的新冠病毒。
NPJ Vaccines. 2024 Sep 18;9(1):173. doi: 10.1038/s41541-024-00961-6.
2
Utilizing Feline Lentiviral Infection to Establish a Translational Model for COVID-19 in People with Human Immunodeficiency Virus Infection.利用猫慢病毒感染建立人类免疫缺陷病毒感染者新冠肺炎的转化模型。
Microorganisms. 2024 Jun 25;12(7):1289. doi: 10.3390/microorganisms12071289.
3
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants.
SARS-CoV-2 之旅：从阿尔法变异株到奥密克戎及其亚变异株。
Infection. 2024 Jun;52(3):767-786. doi: 10.1007/s15010-024-02223-y. Epub 2024 Mar 30.
4
Impact of COVID-19 vaccination: a global perspective.2019冠状病毒病疫苗接种的影响：全球视角
Front Public Health. 2024 Jan 11;11:1272961. doi: 10.3389/fpubh.2023.1272961. eCollection 2023.
5
Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.基因组监测揭示了美国威斯康星州东南部流行的 SARS-CoV-2 奥密克戎谱系中 XBB 谱系的快速扩张。
Viruses. 2023 Sep 16;15(9):1940. doi: 10.3390/v15091940.
6
Targeting SARS-CoV-2 Macrodomain-1 to Restore the Innate Immune Response Using In Silico Screening of Medicinal Compounds and Free Energy Calculation Approaches.利用药物化合物的计算机模拟筛选和自由能计算方法靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的Macrodomain-1以恢复先天免疫反应
Viruses. 2023 Sep 12;15(9):1907. doi: 10.3390/v15091907.
7
The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒发展的终结还是新时代：导致重症冠状病毒病（COVID-19）的基因变体以及临床实践中最常用疫苗的临床疗效
Vaccines (Basel). 2023 Jun 30;11(7):1181. doi: 10.3390/vaccines11071181.
8
Challenges of SARS-CoV-2 genomic surveillance in India during low positivity rate scenario.印度在低阳性率情况下进行 SARS-CoV-2 基因组监测的挑战。
Front Public Health. 2023 Jun 27;11:1117602. doi: 10.3389/fpubh.2023.1117602. eCollection 2023.
9
Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity.高度网络化的 SARS-CoV-2 肽引发具有增强特异性的 T 细胞反应。
Immunohorizons. 2023 Jun 1;7(6):508-527. doi: 10.4049/immunohorizons.2300034.
10
Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity.刺突蛋白P681残基的变化决定了新冠病毒Delta和Omicron变异株的细胞融合及多核巨细胞形成，而对中和作用或感染性无影响。
Heliyon. 2023 Jun;9(6):e16750. doi: 10.1016/j.heliyon.2023.e16750. Epub 2023 Jun 3.